BRNS vs RTX · rev $15.0M vs P/E 36, rev $46.78B
Barinthus Biotherapeutics plc (BRNS) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported BRNS revenue for 2024-12-31 was $15.0M. Net income was -$61.2M. Revenue was up 1766.5% from 2023-12-31 to 2024-12-31. BRNS currently screens at market cap $38.2M.
Latest reported RTX revenue for 2026-06-30 was $46.78B. Net income was $4.20B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
BRNS currently screens at market cap $38.2M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the BRNS and RTX stock pages for the full models.
Not investment advice.